PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.84%
Revenue growth under 50% of MRVL's 10.13%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
1.17%
Gross profit growth under 50% of MRVL's 5.13%. Michael Burry would be concerned about a severe competitive disadvantage.
-4.84%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-4.84%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.33%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-2.63%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.66%
Share count expansion well above MRVL's 0.42%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-1.22%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-66.26%
Negative OCF growth while MRVL is at 260.57%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-110.46%
Negative FCF growth while MRVL is at 572.13%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
461.77%
10Y revenue/share CAGR at 75-90% of MRVL's 568.49%. Bill Ackman would press for new markets or product lines to narrow the gap.
113.91%
5Y revenue/share CAGR under 50% of MRVL's 548.85%. Michael Burry would suspect a significant competitive gap or product weakness.
36.69%
3Y revenue/share CAGR under 50% of MRVL's 151.18%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
428.36%
10Y OCF/share CAGR under 50% of MRVL's 2305.66%. Michael Burry would worry about a persistent underperformance in cash creation.
-76.31%
Negative 5Y OCF/share CAGR while MRVL is at 1502.18%. Joel Greenblatt would question the firm’s operational model or cost structure.
-17.39%
Negative 3Y OCF/share CAGR while MRVL stands at 273.61%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
725.23%
Below 50% of MRVL's 2595.21%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
109.22%
5Y net income/share CAGR at 75-90% of MRVL's 133.11%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
228.36%
3Y net income/share CAGR 75-90% of MRVL's 302.01%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1178.18%
10Y equity/share CAGR 1.25-1.5x MRVL's 805.60%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
153.95%
5Y equity/share CAGR above 1.5x MRVL's 16.84%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
51.87%
3Y equity/share CAGR 1.25-1.5x MRVL's 35.58%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.47%
AR growth well above MRVL's 16.78%. Michael Burry fears inflated revenue or higher default risk in the near future.
9.32%
Inventory growth well above MRVL's 12.82%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.04%
Asset growth well under 50% of MRVL's 5.92%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.18%
Similar to MRVL's 2.19%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
3.96%
R&D dropping or stable vs. MRVL's 22.28%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
5.16%
SG&A growth well above MRVL's 7.21%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.